UK markets open in 6 hours 22 minutes

Altamira Therapeutics Ltd. (CYTO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4800-0.0300 (-1.99%)
At close: 04:00PM EDT
1.5100 +0.03 (+2.03%)
After hours: 06:21PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5100
Open1.5600
Bid1.4300 x 100
Ask1.5300 x 100
Day's range1.4500 - 1.4950
52-week range1.3500 - 17.4600
Volume32,238
Avg. volume1,996,288
Market cap3.316M
Beta (5Y monthly)2.55
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Altamira Therapeutics Provides Business Update

    Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticlesPursuing partnering opportunities with AM-125 legacy asset in vertigo and / or potential other CNS indicationsStreamlining corporate structure; switch in financial reporting from Swiss Francs to US Dollars HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commerci

  • GlobeNewswire

    Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal

    Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that highlights from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR) have been published in video format on the social media channels of Allergy, one of the highest-ranking jour

  • GlobeNewswire

    Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

    Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has filed a provisional patent application with the United States Patent O